Blue bars indicate percentage improvement of the treatment arm over the control arm at time 2x the median, in studies that had less than 20% of patients surviving at time 2x median. Yellow bars indicate percentage improvement of the treatment arm over the control arm at time 2x the median, in studies that had greater than or equal to 20% of patients surviving at time 2x median. Green dots indicate RCTs that did not report OS data at time 2x median. Blue dots indicate RCTs that did not report an OS KM curve. Brown dots indicate RCTs that did not use OS to evaluate the "tail of the curve" bonus. Red dots indicate RCTs that were awarded with a "tail of the curve" bonus on the basis of OS data. Blue bars indicate percentage difference in improvement of the treatment arm and control arm at 12 months or 24 months in RCTs that did not display a "long-term plateau". Yellow bars indicate percentage difference in improvement of the treatment arm and control arm at 12 months or 24 months in RCTs that did display a "long-term plateau". Green dots indicate RCTs that did not report PFS data at the time point assessed (12 months) Dark blue dots indicate that the RCTs did not report PFS data at the time point assessed (24 months) Orange dots indicate RCTs that did not use PFS data to assess the "immunotherapy triggered" long-term plateau adjustment Brown dots indicate RCTs that did not meet eligibility criteria to be scored with the ESMO-MCBS. Red dots indicate RCTs were awarded with the "immunotherapy triggered" long-term plateau adjustment based on PFS data. 
